Predictive Oncology Announces Adjournment of Special Meeting
December 02 2020 - 8:00AM
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company
focused on applying artificial intelligence (“AI”) to personalized
medicine and drug discovery, today announced that its virtual
Special Meeting of Stockholders, scheduled for December 1, 2020,
was convened and adjourned without any business being conducted due
to the fact that quorum was not achieved. The Special Meeting will
be reconvened December 30, 2020 at 3 p.m. CST and will be conducted
via live audio webcast at
www.virtualshareholdermeeting.com/POAI2020SM, so as to allow more
opportunity for stockholders to vote on all proposals described in
the Company’s definitive proxy statement filed with the Securities
and Exchange Commission (SEC) on November 3, 2020.
The record date for the Special Meeting remains
October 28, 2020. Stockholders of record may vote at the reconvened
Special Meeting, vote by proxy using the proxy card enclosed with
the Company’s definitive proxy statement, vote by proxy via
facsimile, email or on the Internet. Whether or not stockholders of
record plan to attend the reconvened Special Meeting, the Company’s
Board of Directors and management urge them to vote by proxy to
ensure their vote is counted. Stockholders who have previously
submitted their proxy or otherwise voted and who do not want to
change their vote need not take any action.
A copy of the Company’s proxy statement as
previously filed with the SEC is available at no charge on the SEC
website at www.sec.gov. In addition, copies of the proxy statement
and other documents may be obtained free of charge by accessing the
Company’s website at https://investors.predictive-oncology.com/ or
by contacting the Company’s Corporate Secretary at (651) 389-4806
or by mail to Corporate Secretary, Predictive Oncology Inc., 2915
Commers Drive, Suite 900, Eagan, MN 55121.
YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE
TODAY!
About Predictive Oncology
Inc.
Predictive Oncology (NASDAQ: POAI) operates
through three segments (Skyline, Helomics and Soluble Biotech),
which contain four subsidiaries: Helomics, TumorGenesis, Skyline
Medical and Soluble Biotech.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
TumorGenesis Inc. specializes in media that help cancer cells grow
and retain their DNA/RNA and proteomic signatures, providing
researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including
humans. Skyline Medical markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement and
disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and
international divisions. Soluble Biotech is a provider of soluble
and stable formulations for proteins including vaccines,
antibodies, large and small proteins and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release
contain forward-looking statements. These forward-looking
statements reflect our current expectations and projections about
future events and are subject to substantial risks, uncertainties
and assumptions about our operations and the investments we make.
All statements, other than statements of historical facts, included
in this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Our actual future
performance may materially differ from that contemplated by the
forward-looking statements as a result of a variety of factors
including, among other things, factors discussed under the heading
“Risk Factors” in our filings with the SEC. Except as expressly
required by law, the Company disclaims any intent or obligation to
update these forward-looking statements.
Investor Relations Contact:
Hayden IRJames Carbonara(646)-755-7412
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024